Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Multiple sclerosis: Daclizumab HYP shows efficacy in patients with relapsing-remitting MS.
Interdisciplinary exchange of ideas: progestagens for autoimmunity, biologics for pregnancy complications.
[Assessment of the high cost drug program on an example of the interferon treatment of multiple sclerosis.]
Current role of chemotherapy and bone marrow transplantation in multiple sclerosis.
[Evaluation of the autonomic regulation of the cardiac oxygen supply of measured physical activity in patients with remitting multiple sclerosis.]
Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica.
[Molecular targeted therapy for neuroimmunological diseases].
Efficacy and safety of alemtuzumab in multiple sclerosis and impact on nursing role.
Correction: Imatinib Ameliorates Neuroinflammation in a Rat Model of Multiple Sclerosis by Enhancing Blood-Brain Barrier Integrity and by Modulating the Peripheral Immune Response.
Tumefactive demyelinating disease with isolated spinal cord involvement.
A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology.
Pío del Río Hortega and the discovery of the oligodendrocytes.
Sex drive and sexual desire.
Pain and Cognition in Multiple Sclerosis.
Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal.
Volumetric MRI assessment of brain and spinal cord in finnish twins discordant for multiple sclerosis.
Neuronal activity biases axon selection for myelination in vivo.
"Microglial nodules" and "newly forming lesions" may be a Janus face of early MS lesions; implications from virus-induced demyelination, the Inside-Out model.
Cerebrospinal fluid analysis in the context of CNS demyelinating diseases.
Soluble Tumor Necrosis Factor Receptor 1 Released by Skin-Derived Mesenchymal Stem Cells Is Critical for Inhibiting Th17 Cell Differentiation.
Pediatric Multiple Sclerosis: Current Concepts and Consensus Definitions.
Remyelinating strategies in multiple sclerosis.
Markedly Increased IP-10 Production by Blood-Brain Barrier in Neuromyelitis Optica.
Serum proteomics in multiple sclerosis disease progression.
Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression.
Pages
« first
‹ previous
…
535
536
537
538
539
540
541
542
543
…
next ›
last »